Cell-specific targeting of lentiviral vectors mediated by fusion proteins derived from Sindbis virus, vesicular stomatitis virus, or avian sarcoma/leukosis virus.

Retrovirology
Xian-Yang ZhangJ Reiser

Abstract

The ability to efficiently and selectively target gene delivery vectors to specific cell types in vitro and in vivo remains one of the formidable challenges in gene therapy. We pursued two different strategies to target lentiviral vector delivery to specific cell types. In one of the strategies, vector particles bearing a membrane-bound stem cell factor sequence plus a separate fusion protein based either on Sindbis virus strain TR339 glycoproteins or the vesicular stomatitis virus G glycoprotein were used to selectively transduce cells expressing the corresponding stem cell factor receptor (c-kit). An alternative approach involved soluble avian sarcoma/leukosis virus receptors fused to cell-specific ligands including stem cell factor and erythropoietin for targeting lentiviral vectors pseudotyped with avian sarcoma/leukosis virus envelope proteins to cells that express the corresponding receptors. The titers of unconcentrated vector particles bearing Sindbis virus strain TR339 or vesicular stomatitis virus G fusion proteins plus stem cell factor in the context of c-kit expressing cells were up to 3.2 x 10(5) transducing units per ml while vector particles lacking the stem cell factor ligand displayed titers that were approxima...Continue Reading

References

May 15, 1994·Archives of Biochemistry and Biophysics·K E LangleyH S Lu
Feb 21, 1997·The Journal of Biological Chemistry·F P BarboneL S Mulcahy
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·S Snitkovsky, J A Young
Aug 18, 1999·Proceedings of the National Academy of Sciences of the United States of America·A L BoergerJ A Young
Jan 11, 2001·Journal of Virology·S SnitkovskyJ A Young
Aug 3, 2001·Journal of Virology·K MorizonoI S Chen
May 7, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Xian-Yang ZhangJakob Reiser
Jun 23, 2005·Cell Cycle·Kouki Morizono, Irvin S Y Chen
Aug 17, 2005·Current Gene Therapy·James CroninJakob Reiser
Jul 26, 2006·Proceedings of the National Academy of Sciences of the United States of America·Lili YangPin Wang
Jul 4, 2007·Nature Reviews. Genetics·Reinhard WaehlerDavid T Curiel
Jul 27, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nonia ParienteIrvin S Y Chen
Dec 13, 2007·The Journal of Gene Medicine·Nonia ParienteIrvin S Y Chen
Feb 26, 2008·Nature Biotechnology·Lili YangPin Wang
Jun 3, 2008·Stem Cells and Development·David M RicksJakob Reiser
Jun 26, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Sabrina FunkeChristian J Buchholz
Jul 2, 2008·Human Gene Therapy·Leslie ZieglerPin Wang
Dec 17, 2008·Current Gene Therapy·Cecilia FrechaEls Verhoeyen
Feb 11, 2009·Cloning and Stem Cells·Martha C GómezJakob Reiser
Mar 21, 2009·Nature Protocols·Robert H KutnerJakob Reiser
May 13, 2009·The Journal of Gene Medicine·Kouki MorizonoIrvin S Y Chen

❮ Previous
Next ❯

Methods Mentioned

BETA
FACS
ELISA
transfection
PCR
X-ray

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.